Catalyzing Innovation: Strategic R&D Investments in India’s Pharma and MedTech Ecosystem
GS3GS2
The government has approved 41 projects under the PRIP scheme, mobilizing ₹4,620 crore to bolster indigenous R&D in drug discovery and medical technology, aiming to reduce import dependency and enhance global competitiveness.
The Indian pharmaceutical and medical technology sector is undergoing a structural shift from being a 'pharmacy of the world' based on generic manufacturing to becoming a hub for high-end research and innovation. The recent approval of 41 projects under the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme marks a significant policy intervention to bridge the gap between academic research and industrial application.
With a total R&D investment of ₹4,620 crore, the initiative focuses on critical areas such as novel drug discovery, clinical development, and the creation of advanced medical devices. A key priority is addressing the growing global challenge of antimicrobial resistance (AMR) through the development of new antibacterial agents. Furthermore, the emphasis on point-of-care diagnostic platforms reflects a strategic move to democratize healthcare access, ensuring that sophisticated diagnostic tools are available even in resource-constrained settings.
Continue reading — free with login
JeetoBharat publishes daily UPSC current affairs mapped to the Mains syllabus. Log in to read full articles.
Log in to read full articleNo credit card required. Free registered users get unlimited access.
This article was curated using AI. While we strive for accuracy, please verify critical facts from official sources.